Northwest Biotherapeutics, Inc. is a development-stage American pharmaceutical company headquartered in Maryland that focuses on developing immunotherapies against different types of cancer. It was founded in 1996 by Alton L. Boynton.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | 2025-10-16 14:58:07 | 0.23 | -0.01 | -3.4 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NWBO | 0001072379 | NORTHWEST BIOTHERAPEUTICS INC | US66737P6007 | 5493002DRWWEOWTT8005 | 943306718 | OTC | 2834 | Pharmaceutical Preparations | 1231 | DE | 4800 MONTGOMERY LANE | BETHESDA | MD | 20814 | UNITED STATES | US | (240) 497-9024 | 4800 MONTGOMERY LANE, BETHESDA, MD, 20814 | 4800 MONTGOMERY LANE, BETHESDA, MD, 20814 | — | Pharmaceuticals | 1998-01-01 | — | — | http://nwbio.com | 510,810,000 | 1,458,800,000 | 1,482,346,009 | Northwest Biotherapeutics, Inc. is a development-stage American pharmaceutical company headquartered in Maryland that focuses on developing immunotherapies against different types of cancer. It was founded in 1996 by Alton L. Boynton. | 2025-10-10 21:59:08 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 510,810,000 | -106,409,000 | -17.2401 | 1,390,753,061 | 195,395,244 | 16.3462 |
| 2023 | 617,219,000 | -13,255,000 | -2.1024 | 1,195,357,817 | 122,478,738 | 11.4159 |
| 2022 | 630,474,000 | -582,288,000 | -48.0134 | 1,072,879,079 | 112,856,962 | 11.7557 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Marnix L. Bosch, Ph.D. | Chief Technical Officer | 2023 | 453,600 | 0 | — | — | — | 453,600 |
| Alton L. Boynton | Secretary, Chief Scientific Officer | 2023 | 375,000 | 0 | — | — | — | 375,000 |
| Linda F. Powers | Chief Executive Officer, Chairperson, President | 2023 | 925,000 | 0 | — | — | — | 925,000 |
| Leslie Goldman | General Counsel, Senior Vice President | 2023 | 725,000 | 0 | — | — | — | 725,000 |
| Leslie Goldman | General Counsel, Senior Vice President | 2022 | 525,000 | 300,000 | — | — | — | 825,000 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 25 |
| 2023 | 25 |
| 2022 | 22 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 1,382,000 | 1,932,000 | 1,683,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 34,888,000 | 27,730,000 | 35,511,000 |
| General And Administrative Expenses | 33,002,000 | 29,710,000 | 33,353,000 |
| Operating Expenses | — | — | — |
| Operating Income | -66,508,000 | -55,508,000 | -67,181,000 |
| Net Income | -83,778,000 | -62,599,000 | -105,032,000 |
| Earnings Per Share Basic | -0.07 | -0.06 | -0.1 |
| Earnings Per Share Diluted | -0.07 | -0.06 | -0.1 |
| Weighted Average Shares Outstanding Basic | 1,242,237 | 1,119,191 | 1,015,852 |
| Weighted Average Shares Outstanding Diluted | 1,242,237 | 1,119,191 | 1,015,852 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 2,175,000 | 2,126,000 | 6,965,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | — | — | — |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 4,062,000 | 4,125,000 | 9,425,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 16,196,000 | 17,278,000 | 13,418,000 |
| Other Assets Non Current | 365,000 | 361,000 | 345,000 |
| Total Assets Non Current | 22,666,000 | 23,740,000 | 21,898,000 |
| Total Assets | 26,728,000 | 27,865,000 | 31,323,000 |
| Accounts Payable | 16,969,000 | 10,244,000 | 10,687,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 68,274,000 | 45,204,000 | 126,005,000 |
| Long Term Debt | 62,676,000 | 40,792,000 | 21,529,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 37,434,000 | 29,716,000 | 10,361,000 |
| Total Liabilities | 105,708,000 | 74,920,000 | 136,366,000 |
| Common Stock | 1,328,000 | 1,175,000 | 1,068,000 |
| Retained Earnings | -1,443,499,000 | -1,359,721,000 | -1,297,122,000 |
| Accumulated Other Comprehensive Income | 3,043,000 | 1,536,000 | 3,145,000 |
| Total Shareholders Equity | -94,487,000 | -65,773,000 | -128,103,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 1,744,000 | 1,525,000 | 1,252,000 |
| Share Based Compensation Expense | 3,456,000 | 3,600,000 | 1,400,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -57,017,000 | -53,637,000 | -52,775,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | — | — | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -1,014,000 | -3,437,000 | -2,902,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 14,217,000 | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 56,785,000 | 52,758,000 | 41,968,000 |
| Change In Cash | 49,000 | -4,839,000 | -8,204,000 |
| Cash At End Of Period | 2,175,000 | 2,126,000 | 6,965,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 130,000 | 5,241,000 | 6,068,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.07 | -0.06 | -0.1 |
| Price To Earnings Ratio | -3.9243 | -11.6833 | -7.845 |
| Earnings Growth Rate | 16.6667 | -40 | -147.619 |
| Price Earnings To Growth Ratio | -0.2355 | 0.2921 | 0.0531 |
| Book Value Per Share | -63.5789 | -42.0438 | -103.4038 |
| Price To Book Ratio | -0.0043 | -0.0167 | -0.0076 |
| Ebitda | -74,267,000 | -55,833,000 | -97,712,000 |
| Enterprise Value | 60,842,242.5039 | 39,450,552.891 | 15,360,935.894 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -0.6633 | -0.6202 | -0.1681 |
| Capital Expenditures | 662,000 | 5,385,000 | -357,000 |
| Free Cash Flow | -57,679,000 | -59,022,000 | -52,418,000 |
| Return On Equity | 0.8867 | 0.9517 | 0.8199 |
| One Year Beta | 0.6698 | 0.0354 | 0.0864 |
| Three Year Beta | 0.1709 | 0.1998 | 0.4088 |
| Five Year Beta | 0.3965 | 0.4184 | 0.4155 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| BOYNTON ALTON L | Director, CHIEF SCIENTIFIC OFFICER | 2024-08-29 | 1,000,000 | D | 967,065 |
| BOSCH MARNIX L | CHIEF TECHNICAL OFFICER | 2024-08-09 | 3,000,000 | D | 4,549,157 |
| BOYNTON ALTON L | Director, CHIEF SCIENTIFIC OFFICER | 2024-08-08 | 1,000,000 | D | 1,967,065 |
| MALIK NAVID | Director | 2024-07-26 | 657,895 | D | 23,339,393 |
| MALIK NAVID | Director | 2023-11-17 | 150,000 | A | 295,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Williams Jones Wealth Management, LLC. | 2025-06-30 | 6,477 | 27,000 | 0.2399 |
| VSM Wealth Advisory, LLC | 2025-06-30 | 15,731 | 65,574 | 0.2399 |
| Ethos Financial Group, LLC | 2025-06-30 | 12,593 | 49,050 | 0.2567 |
| Opus Capital Group, LLC | 2025-06-30 | 14,000 | 60,150 | 0.2328 |
| ADVISORS MANAGEMENT GROUP INC /ADV | 2025-06-30 | 2,000 | 10,270 | 0.1947 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 2023-06-30 | NAV | JAFEX | 11,656 | 6,620.61 | 0.0009 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 2023-06-30 | Series I | JETSX | 11,656 | 6,620.61 | 0.0009 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 2023-06-30 | Series II | JAFFX | 11,656 | 6,620.61 | 0.0009 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 2023-03-31 | NAV | JAFEX | 11,656 | 7,285 | 0.001 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 2023-03-31 | Series I | JETSX | 11,656 | 7,285 | 0.001 |